Phospholamban mutants compete with wild type for SERCA binding in living cells

Biochemical and Biophysical Research Communications

Volumn 420, Issue 2, 2012, Pages 236-240

  Gruber, Simon J ^a   Haydon, Suzanne ^a   Thomas, David D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Competition; FRET; HEK; PLB; SERCA

Indexed keywords

CYAN FLUORESCENT PROTEIN; FORSKOLIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; YELLOW FLUORESCENT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL LINE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TRANSIENT EXPRESSION; WILD TYPE;

BINDING, COMPETITIVE; CALCIUM-BINDING PROTEINS; ENZYME ACTIVATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC THERAPY; HEART FAILURE; HEK293 CELLS; HUMANS; LUMINESCENT PROTEINS; PHOSPHORYLATION; RECOMBINANT FUSION PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84863419025     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.125     Document Type: Article

References (26)

1. Simmerman H.K., Collins J.H., Theibert J.L., Wegener A.D., Jones L.R. Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J. Biol. Chem. 1986, 261:13333-13341.
2. MacLennan D.H., Kranias E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell. Biol. 2003, 4:566-577.
3. Frank K.F., Bolck B., Brixius K., Kranias E.G., Schwinger R.H. Modulation of SERCA: implications for the failing human heart. Basic Res. Cardiol. 2002, 97(Suppl 1):172-178.
4. 2+-ATPase in patients with advanced heart failure. Circulation 2011, 124:304-313.
5. Hasenfuss G., Teerlink J.R. Cardiac inotropes: current agents and future directions. Eur. Heart J. 2011, 32:1838-1845.
6. Hoshijima M., Ikeda Y., Iwanaga Y., Minamisawa S., Date M.O., Gu Y., Iwatate M., Li M., Wang L., Wilson J.M., Wang Y., Ross J., Chien K.R. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 2002, 8:864-871.
7. Nicolaou P., Hajjar R.J., Kranias E.G. Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J. Mol. Cell. Cardiol. 2009, 47:365-371.
8. 2+, but not by phospholamban phosphorylation, vanadate, or thapsigargin, and are enhanced by ATP. J. Biol. Chem. 2000, 275:15034-15038.
9. 2+ pump is sufficient to dissociate phospholamban. J. Biol. Chem. 2010, 285:3253-3260.
10. 2+-dependent ATPase following phosphorylation by cAMP-dependent protein kinase. Biochem. J. 2000, 351:195-205.
11. Mueller B., Karim C.B., Negrashov I.V., Kutchai H., Thomas D.D. Direct detection of phospholamban and sarcoplasmic reticulum Ca-ATPase interaction in membranes using fluorescence resonance energy transfer. Biochemistry 2004, 43:8754-8765.
12. Karim C.B., Zhang Z., Howard E.C., Torgersen K.D., Thomas D.D. Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA. J. Mol. Biol. 2006, 358:1032-1040.
13. Bidwell P., Blackwell D.J., Hou Z., Zima A.V., Robia S.L. Phospholamban binds with differential affinity to calcium pump conformers. J. Biol. Chem. 2011, 286:35044-35050.
14. Lockamy E.L., Cornea R.L., Karim C.B., Thomas D.D. Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. Biochem. Biophys. Res. Commun. 2011, 408:388-392.
15. 2+-ATPase expressed in COS-1 cells. Proc. Natl. Acad. Sci. USA 1988, 85:3314-3318.
16. Birmachu W., Nisswandt F.L., Thomas D.D. Conformational transitions in the calcium adenosinetriphosphatase studied by time-resolved fluorescence resonance energy transfer. Biochemistry 1989, 28:3940-3947.
17. Ablorh N.A., Nitu F., Engebretsen K., Thomas D.D., Holger J.S. Insulin-dependent rescue from cardiogenic shock is not mediated by phospholamban phosphorylation. Clin. Toxicol. (Phila) 2009, 47:296-302.
18. N.-A. Ablorh, T. Miller, F.R. Nitu, S.J. Gruber, C.B. Karim, D.D. Thomas, Accurate quantitation of phospholamban phosphorylation by immunoblot, Anal. Biochem. (2012) (accepted).
19. Autry J.M., Rubin J.E., Pietrini S.D., Winters D.L., Robia S.L., Thomas D.D. Oligomeric interactions of sarcolipin and the Ca-ATPase. J. Biol. Chem. 2011, 286:31697-31706.
20. Kelly E.M., Hou Z., Bossuyt J., Bers D.M., Robia S.L. Phospholamban oligomerization, quaternary structure, and sarco(endo)plasmic reticulum calcium ATPase binding measured by fluorescence resonance energy transfer in living cells. J. Biol. Chem. 2008, 283:12202-12211.
21. 2+-ATPase isoform of cardiac sarcoplasmic reticulum. J. Biol. Chem. 1998, 273:14238-14241.
22. Robia S.L., Campbell K.S., Kelly E.M., Hou Z., Winters D.L., Thomas D.D. Forster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex. Circ. Res. 2007, 101:1123-1129.
23. Winters D.L., Autry J.M., Svensson B., Thomas D.D. Interdomain fluorescence resonance energy transfer in SERCA probed by cyan-fluorescent protein fused to the actuator domain. Biochemistry 2008, 47:4246-4256.
24. Crystal R.G. Cardiac gene therapy: pumping the heart. Gene Therapy 2003, 10:2-3.
25. 2+-ATPase by tuning phospholamban structural dynamics. J. Biol. Chem. 2007, 282:37205-37214.
26. Muretta J.M., Kyrychenko A., Ladokhin A.S., Kast D.J., Gillispie G.D., Thomas D.D. High-performance time-resolved fluorescence by direct waveform recording. Rev. Sci. Instrum. 2010, 81:103101.